Abstract
Get full access to this article
View all access options for this article.
References
1.Compendium of Pharmaceuticals and Specialties. 28th edition. Ottawa, Ontario : Canadian Pharmaceutical Association , 1993 .
2.
Ganzini L.
,
Casey D.E.
,
Hoffman W.F.
,
McCall A.L.
Prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders . Arch Intern Med 1993 ; 153 : 1469 –1475 .
3.
Albibi R.
,
McCallum R.W.
Metoclopramide: pharmacology and clinical application . Ann Intern Med 1983 ; 98 : 86 –95 .
4.
Lichter I.
Which antiemetic? J Palliat Care 1993 ; 9 (1 ): 42 –50 .
5.
Ferrando S.J.
,
Eisendrath S.J.
Adverse neuropsychiatric effects of dopamine antagonist medications: misdiagnosis in the medical setting . Psychosomatics 1991 ; 32 : 426 –432 .
6.
Miller L.G.
,
Jankovic J.
Metoclopramide-induced movement disorders: clinical findings with a review of the literature . Arch Intern Med 1989 ; 149 : 2486 –2492 .
7.
Hyser C.L.
,
Drake M.E.
Jr.
Myoclonus induced by metoclopramide therapy . Arch Intern Med 1983 ; 143 : 2201 –2202 .
8.
Grimes J.D.
,
Hassan M.N.
,
Preston D.N.
Adverse neurologic effects of metoclopramide . Can Med Assoc J 1982 ; 126 : 23 –25 .